Metyltioniini tutkimuksissa

http://en.wikipedia.org/wiki/Methylthioninium_chloride
Metyltioniini eli metyleenisini on redusoiva ( pelkistävä) aine, jota käytetään terapeuttisesti joissain methemoglobinemiamuodoissa palauttamassa hemoglobiinin Ferrirautaa Hb-Fe+++  ferro-muotoon Hb-Fe++.
 On havaittu että  metyleenisini toimii myös  Tau-proteiinin aggrekaation estäjänä, jolloin  se on kiinnostava aine  mahdollisena  Alzheimerin taudin lääkekirjoon kuuluvana  uutena jäsenenä. Mahdollista edullista vaikutusta sillä lie myös Parkinsonin tautiin. Asiaa tutkitaan.

SITAATTI Wikipediasta:

Methylthioninium chloride

For other uses of the chemical compound methylthioninium chloride, see Methylene blue.

Methylthioninium chloride

Systematic (IUPAC) name
3,7-bis(Dimethylamino)-phenothiazin-5-ium chloride
Clinical data
Pregnancy cat.	?
Legal status	investigational
Routes	oral
Identifiers
CAS number	61-73-4
ATC code	None
PubChem	CID 6099
ChemSpider	5874
ChEBI	CHEBI:6872
ChEMBL	CHEMBL405110
Chemical data
Formula	C16H18ClN3S
Mol. mass	319.85 g/mol
SMILES[show]
InChI[show]
(what is this?)  (verify)

Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation.^[1][2] The drug is of potential interest for the treatment of patients with Alzheimer's disease. Its development appears to be related to claim 7 of US 6953794 Inhibition of Tau-Tau Association. TauRx Therapeutics has suggested that the mechanism by which methylene blue might delay or reverse neurodegeneration in Alzheimer's disease is as an inhibitor of Tau protein aggregation. While methylene blue arguably has an effect on Tau aggregation, it also has an effect on mitochondrial function which is likely to play an important role. In vitro studies suggest that methylene blue might be an effective remedy for both Alzheimer's and Parkinson's disease by enhancing key mitochondrial biochemical pathways. It can disinhibit and increase complex IV, whose inhibition correlates with Alzheimer's disease. ^[3]

Contents

• 1 2008 clinical trial results
• 2 Phase III trial
• 3 See also
• 4 References
• 5 External links

...